{"product_id":"larazotide-20mg","title":"Larazotide 20mg – Research Peptide","description":"\u003ch3 data-section-id=\"5phdk4\" data-start=\"354\" data-end=\"431\"\u003eLarazotide Acetate – Intestinal Barrier and Tight Junction Research Peptide\u003c\/h3\u003e\n\u003ch3 data-section-id=\"cibsat\" data-start=\"433\" data-end=\"445\"\u003eOverview\u003c\/h3\u003e\n\u003cp data-start=\"447\" data-end=\"672\"\u003eLarazotide acetate (AT-1001) is a synthetic 8-amino-acid peptide (sequence: Gly-Gly-Val-Leu-Val-Gln-Pro-Gly; GGVLVQPG) investigated in research models of intestinal barrier regulation and epithelial tight junction dynamics.\u003c\/p\u003e\n\u003cp data-start=\"674\" data-end=\"862\"\u003eIt is commonly referenced in studies examining zonulin-associated signaling pathways and the molecular mechanisms that influence paracellular permeability within the intestinal epithelium.\u003c\/p\u003e\n\u003cp data-start=\"864\" data-end=\"1046\"\u003eUnlike many systemically active peptides, larazotide is designed to act primarily within the intestinal lumen, where it interacts locally with epithelial barrier signaling processes.\u003c\/p\u003e\n\u003ch3 data-section-id=\"o4rtew\" data-start=\"1053\" data-end=\"1084\"\u003eMolecular Mechanism of Action\u003c\/h3\u003e\n\u003cp data-start=\"1086\" data-end=\"1263\"\u003eLarazotide is studied as a \u003cstrong data-start=\"1113\" data-end=\"1172\"\u003ecompetitive antagonist of the zonulin signaling pathway\u003c\/strong\u003e, a regulatory system involved in the modulation of epithelial tight junction permeability.\u003c\/p\u003e\n\u003ch3 data-section-id=\"vmv2z6\" data-start=\"1265\" data-end=\"1305\"\u003eZonulin-Associated Signaling Cascade\u003c\/h3\u003e\n\u003cp data-start=\"1307\" data-end=\"1526\"\u003eIn experimental models, intestinal permeability can increase when zonulin is released by enterocytes in response to environmental triggers such as microbial products, inflammatory cytokines, or certain dietary peptides.\u003c\/p\u003e\n\u003cp data-start=\"1528\" data-end=\"1571\"\u003eThe pathway proceeds through several steps:\u003c\/p\u003e\n\u003col data-start=\"1573\" data-end=\"1595\"\u003e\n\u003cli data-section-id=\"qd2dee\" data-start=\"1573\" data-end=\"1595\"\u003e\n\u003cp data-start=\"1576\" data-end=\"1595\"\u003e\u003cstrong data-start=\"1576\" data-end=\"1595\"\u003eZonulin release\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp data-start=\"1597\" data-end=\"1745\"\u003eCertain luminal stimuli activate CXCR3-MyD88 signaling in enterocytes, leading to secretion of zonulin (prehaptoglobin-2) into the intestinal lumen.\u003c\/p\u003e\n\u003col start=\"2\" data-start=\"1747\" data-end=\"1774\"\u003e\n\u003cli data-section-id=\"1lol22z\" data-start=\"1747\" data-end=\"1774\"\u003e\n\u003cp data-start=\"1750\" data-end=\"1774\"\u003e\u003cstrong data-start=\"1750\" data-end=\"1774\"\u003eReceptor interaction\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp data-start=\"1776\" data-end=\"1986\"\u003eZonulin binds to receptors on the \u003cstrong data-start=\"1810\" data-end=\"1844\"\u003eapical membrane of enterocytes\u003c\/strong\u003e, particularly \u003cstrong data-start=\"1859\" data-end=\"1899\"\u003eprotease-activated receptor-2 (PAR2)\u003c\/strong\u003e, which can subsequently transactivate the \u003cstrong data-start=\"1942\" data-end=\"1985\"\u003eepidermal growth factor receptor (EGFR)\u003c\/strong\u003e.\u003c\/p\u003e\n\u003col start=\"3\" data-start=\"1988\" data-end=\"2029\"\u003e\n\u003cli data-section-id=\"19celmm\" data-start=\"1988\" data-end=\"2029\"\u003e\n\u003cp data-start=\"1991\" data-end=\"2029\"\u003e\u003cstrong data-start=\"1991\" data-end=\"2029\"\u003eIntracellular signaling activation\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp data-start=\"2031\" data-end=\"2092\"\u003eThis interaction activates phospholipase C (PLC), leading to:\u003c\/p\u003e\n\u003cul data-start=\"2094\" data-end=\"2196\"\u003e\n\u003cli data-section-id=\"47notx\" data-start=\"2094\" data-end=\"2119\"\u003e\n\u003cp data-start=\"2096\" data-end=\"2119\"\u003eIP3 and DAG signaling\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-section-id=\"awcxnp\" data-start=\"2120\" data-end=\"2155\"\u003e\n\u003cp data-start=\"2122\" data-end=\"2155\"\u003eintracellular Ca²⁺ mobilization\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-section-id=\"16y0kun\" data-start=\"2156\" data-end=\"2196\"\u003e\n\u003cp data-start=\"2158\" data-end=\"2196\"\u003eactivation of protein kinase Cα (PKCα)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003col start=\"4\" data-start=\"2198\" data-end=\"2228\"\u003e\n\u003cli data-section-id=\"1025c4r\" data-start=\"2198\" data-end=\"2228\"\u003e\n\u003cp data-start=\"2201\" data-end=\"2228\"\u003e\u003cstrong data-start=\"2201\" data-end=\"2228\"\u003eCytoskeletal remodeling\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp data-start=\"2230\" data-end=\"2260\"\u003eDownstream signaling promotes:\u003c\/p\u003e\n\u003cul data-start=\"2262\" data-end=\"2392\"\u003e\n\u003cli data-section-id=\"16ahnd7\" data-start=\"2262\" data-end=\"2336\"\u003e\n\u003cp data-start=\"2264\" data-end=\"2336\"\u003ephosphorylation of \u003cstrong data-start=\"2283\" data-end=\"2311\"\u003emyosin light chain (MLC)\u003c\/strong\u003e via MLCK\/ROCK pathways\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-section-id=\"1qsdsjv\" data-start=\"2337\" data-end=\"2392\"\u003e\n\u003cp data-start=\"2339\" data-end=\"2392\"\u003econtraction of the \u003cstrong data-start=\"2358\" data-end=\"2392\"\u003eperijunctional actomyosin ring\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003col start=\"5\" data-start=\"2394\" data-end=\"2429\"\u003e\n\u003cli data-section-id=\"v9ze9r\" data-start=\"2394\" data-end=\"2429\"\u003e\n\u003cp data-start=\"2397\" data-end=\"2429\"\u003e\u003cstrong data-start=\"2397\" data-end=\"2429\"\u003eTight junction rearrangement\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp data-start=\"2431\" data-end=\"2514\"\u003eThis process can result in redistribution of key tight junction proteins including:\u003c\/p\u003e\n\u003cul data-start=\"2516\" data-end=\"2579\"\u003e\n\u003cli data-section-id=\"132jsld\" data-start=\"2516\" data-end=\"2528\"\u003e\n\u003cp data-start=\"2518\" data-end=\"2528\"\u003e\u003cstrong data-start=\"2518\" data-end=\"2526\"\u003eZO-1\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-section-id=\"1ln1t31\" data-start=\"2529\" data-end=\"2545\"\u003e\n\u003cp data-start=\"2531\" data-end=\"2545\"\u003e\u003cstrong data-start=\"2531\" data-end=\"2543\"\u003eoccludin\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-section-id=\"yz2n4z\" data-start=\"2546\" data-end=\"2562\"\u003e\n\u003cp data-start=\"2548\" data-end=\"2562\"\u003e\u003cstrong data-start=\"2548\" data-end=\"2560\"\u003eclaudins\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-section-id=\"cj802m\" data-start=\"2563\" data-end=\"2579\"\u003e\n\u003cp data-start=\"2565\" data-end=\"2579\"\u003e\u003cstrong data-start=\"2565\" data-end=\"2579\"\u003eE-cadherin\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"2581\" data-end=\"2740\"\u003eThe resulting structural changes may increase \u003cstrong data-start=\"2627\" data-end=\"2656\"\u003eparacellular permeability\u003c\/strong\u003e, allowing macromolecules or luminal antigens to pass across the epithelial barrier.\u003c\/p\u003e\n\u003ch3 data-section-id=\"1m23dbz\" data-start=\"2747\" data-end=\"2801\"\u003e\u003c\/h3\u003e\n\u003cp data-start=\"2928\" data-end=\"2977\"\u003e \u003c\/p\u003e\n\u003ch3 data-section-id=\"x0xfe9\" data-start=\"3706\" data-end=\"3754\"\u003eFindings from Cellular and Experimental Models\u003c\/h3\u003e\n\u003cp data-start=\"3756\" data-end=\"3954\"\u003eIn commonly used epithelial cell models (including \u003cstrong data-start=\"3807\" data-end=\"3856\"\u003eCaco-2, MDCK, IEC-6, and intestinal organoids\u003c\/strong\u003e), larazotide exposure has been associated with measurable changes in barrier function indicators:\u003c\/p\u003e\n\u003cp data-start=\"3956\" data-end=\"4186\"\u003e• Increased \u003cstrong data-start=\"3968\" data-end=\"4016\"\u003etransepithelial electrical resistance (TEER)\u003c\/strong\u003e\u003cbr data-start=\"4016\" data-end=\"4019\"\u003e• Reduced \u003cstrong data-start=\"4029\" data-end=\"4068\"\u003eparacellular flux of macromolecules\u003c\/strong\u003e (e.g., FITC-dextran)\u003cbr data-start=\"4089\" data-end=\"4092\"\u003e• Preservation of tight junction protein localization during inflammatory or stress conditions\u003c\/p\u003e\n\u003cp data-start=\"4188\" data-end=\"4292\"\u003eThese findings have positioned larazotide as a compound frequently used in laboratory studies exploring:\u003c\/p\u003e\n\u003cul data-start=\"4294\" data-end=\"4416\"\u003e\n\u003cli data-section-id=\"wf19nu\" data-start=\"4294\" data-end=\"4332\"\u003e\n\u003cp data-start=\"4296\" data-end=\"4332\"\u003eintestinal permeability regulation\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-section-id=\"q1q9q\" data-start=\"4333\" data-end=\"4364\"\u003e\n\u003cp data-start=\"4335\" data-end=\"4364\"\u003eepithelial barrier dynamics\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-section-id=\"1a2efgc\" data-start=\"4365\" data-end=\"4416\"\u003e\n\u003cp data-start=\"4367\" data-end=\"4416\"\u003eimmune-epithelial interaction at mucosal surfaces\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-section-id=\"zlqbtv\" data-start=\"4423\" data-end=\"4475\"\u003eResearch Context: Gut Barrier and Immune Signaling\u003c\/h3\u003e\n\u003cp data-start=\"4477\" data-end=\"4655\"\u003eBarrier integrity of the intestinal epithelium is increasingly studied as an important interface between microbial exposure, immune signaling, and systemic inflammatory pathways.\u003c\/p\u003e\n\u003cp data-start=\"4657\" data-end=\"4754\"\u003eExperimental literature has explored whether modulation of epithelial permeability may influence:\u003c\/p\u003e\n\u003cul data-start=\"4756\" data-end=\"4872\"\u003e\n\u003cli data-section-id=\"16pt98t\" data-start=\"4756\" data-end=\"4791\"\u003e\n\u003cp data-start=\"4758\" data-end=\"4791\"\u003emicrobial antigen translocation\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-section-id=\"u2819a\" data-start=\"4792\" data-end=\"4814\"\u003e\n\u003cp data-start=\"4794\" data-end=\"4814\"\u003ecytokine signaling\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-section-id=\"1ainr7i\" data-start=\"4815\" data-end=\"4872\"\u003e\n\u003cp data-start=\"4817\" data-end=\"4872\"\u003eimmune cell trafficking from the intestinal environment\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"4874\" data-end=\"5121\"\u003eAnimal studies investigating autoimmune and inflammatory models have reported that restoration of epithelial barrier integrity can influence systemic immune responses, including modulation of T-cell populations and inflammatory signaling pathways.\u003c\/p\u003e\n\u003cp data-start=\"5123\" data-end=\"5261\"\u003eLarazotide has therefore been examined in research settings focused on \u003cstrong data-start=\"5194\" data-end=\"5226\"\u003egut-immune axis interactions\u003c\/strong\u003e and epithelial barrier regulation.\u003c\/p\u003e\n\u003ch3 data-section-id=\"6tnc4l\" data-start=\"5268\" data-end=\"5298\"\u003eClinical Development Context\u003c\/h3\u003e\n\u003cp data-start=\"5300\" data-end=\"5425\"\u003eLarazotide acetate has been investigated in multiple clinical research programs examining intestinal permeability modulation.\u003c\/p\u003e\n\u003cp data-start=\"5427\" data-end=\"5500\"\u003eClinical trials have primarily explored larazotide in contexts involving:\u003c\/p\u003e\n\u003cul data-start=\"5502\" data-end=\"5619\"\u003e\n\u003cli data-section-id=\"1fbr3ro\" data-start=\"5502\" data-end=\"5536\"\u003e\n\u003cp data-start=\"5504\" data-end=\"5536\"\u003eepithelial barrier dysfunction\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-section-id=\"b67wo0\" data-start=\"5537\" data-end=\"5580\"\u003e\n\u003cp data-start=\"5539\" data-end=\"5580\"\u003egluten-triggered permeability responses\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-section-id=\"15p3k4o\" data-start=\"5581\" data-end=\"5619\"\u003e\n\u003cp data-start=\"5583\" data-end=\"5619\"\u003einflammatory intestinal environments\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"5621\" data-end=\"5796\"\u003eAcross published studies, larazotide has demonstrated a \u003cstrong data-start=\"5677\" data-end=\"5739\"\u003efavorable safety profile and localized mechanism of action\u003c\/strong\u003e, consistent with its design as a gut-restricted peptide.\u003c\/p\u003e\n\u003cp data-start=\"5798\" data-end=\"5929\"\u003eThe compound remains \u003cstrong data-start=\"5819\" data-end=\"5862\"\u003einvestigational and under ongoing study\u003c\/strong\u003e in several research programs examining epithelial barrier biology.\u003c\/p\u003e\n\u003ch3 data-section-id=\"15vs70q\" data-start=\"5936\" data-end=\"5963\"\u003eMolecular Characteristics\u003c\/h3\u003e\n\u003cp data-start=\"5965\" data-end=\"6234\"\u003e\u003cstrong data-start=\"5965\" data-end=\"5978\"\u003eSynonyms:\u003c\/strong\u003e Larazotide acetate, AT-1001\u003cbr data-start=\"6006\" data-end=\"6009\"\u003e\u003cstrong data-start=\"6009\" data-end=\"6030\"\u003ePeptide Sequence:\u003c\/strong\u003e Gly-Gly-Val-Leu-Val-Gln-Pro-Gly (GGVLVQPG)\u003cbr data-start=\"6073\" data-end=\"6076\"\u003e\u003cstrong data-start=\"6076\" data-end=\"6098\"\u003eMolecular Formula:\u003c\/strong\u003e C₃₂H₅₅N₉O₁₀\u003cbr data-start=\"6110\" data-end=\"6113\"\u003e\u003cstrong data-start=\"6113\" data-end=\"6146\"\u003eMolecular Weight:\u003c\/strong\u003e ~725.8 g\/mol\u003cbr\u003e\u003cstrong\u003eCAS: \u003c\/strong\u003e258818-34-7\u003c\/p\u003e\n\u003ch3 class=\"flex items-end font-medium leading-tight break-words text-2xl lg:text-3xl\"\u003e\u003cspan class=\"flex-1\"\u003eStructures:\u003c\/span\u003e\u003c\/h3\u003e\n\u003cdiv style=\"text-align: start;\"\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0908\/7113\/6522\/files\/Larazotide.png?v=1772793744\" alt=\"Larazotide structure\" style=\"margin-bottom: 16px; float: none;\"\u003e\u003c\/div\u003e\n\u003cdiv style=\"text-align: start;\"\u003e\u003ca href=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/9810532\"\u003eSource: PubChem\u003c\/a\u003e\u003c\/div\u003e","brand":"PRG","offers":[{"title":"Vial","offer_id":52641934672138,"sku":null,"price":240.0,"currency_code":"EUR","in_stock":true},{"title":"Pre-filled Pen ( 1 )","offer_id":52641934704906,"sku":null,"price":265.0,"currency_code":"EUR","in_stock":true},{"title":"Capsules","offer_id":53149016391946,"sku":null,"price":290.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0908\/7113\/6522\/files\/Larazotide20mg_4_1.png?v=1780478333","url":"https:\/\/www.peptideregenesis.com\/products\/larazotide-20mg","provider":"PRG","version":"1.0","type":"link"}